



Evofem Biosciences to Present at LD Micro Invitational XI on Tuesday, June 8, 2021

SAN DIEGO, May 25, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its CEO Sandra Pelletier will present at the 2021 LD Micro Invitational XI on Tuesday, June 8, 2021 at 1:00 p.m. ET (10:00 a.m. PT).

Pelletier will provide an update on the commercialization of Evofem's hormone-free contraceptive **Phexxi® (lactic acid, citric acid and potassium bitartrate)**, the ongoing Phase 3 clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women, and other ongoing initiatives.

To pre-register for the presentation, please visit <https://ldmicrojune2021.mysequire.com/>.

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). For more information, please visit evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact

Amy Raskopf

Evofem Biosciences, Inc.

araskopf@evofem.com

Mobile: (917) 673-5775

SOURCE Evofem Biosciences, Inc.